ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pomalidomide

Also written as “Pomalidomide”, “Pomalidomide 4 MG Oral Capsule” and “Xetrane® (Pomalidomide) 4 mg Hard Capsule”.

Its studies are mostly in Multiple Myeloma · Primary Myelofibrosis · Brain Neoplasms · Scleroderma, Systemic · Hematologic Neoplasms, led by 8 companies.

Drug pagePomalidomide: every studyMany companies study it; this page follows only the 37 they lead. All 160 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 15, 201037 company-led studies, 2 open or runningNext primary completion: Jan 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only251 open or runningphase 3since Jul 15, 2010Nov 7, 2003Jan 10, 2027phase 3 · NCT05519085
Oncotherapeuticsits history only40 open or runningphase 2since Feb 20, 2012Feb 20, 2012none ahead
Amgenits history only20 open or runningphase 2since Nov 22, 2019Oct 18, 2016none ahead
Simcere Pharmaceutical Groupits history only20 open or runningphase 3since Sep 24, 2016Sep 24, 2016none ahead
Criterium10 open or runningphase 2since Oct 19, 2011Oct 19, 2011none ahead
Knight Therapeutics (USA)its history only10 open or runningphase 1since Jul 3, 2026Jul 3, 2026none ahead
Megalabsits history only11 open or runningphase 1since Sep 15, 2023Sep 15, 2023none ahead
Takedaits history only10 open or runningphase 4since Dec 20, 2021Dec 20, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Criterium only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2011First study: phase 2 study in Multiple MyelomaFirst studyNCT01464034 · 136 enrolled · United States

TargetBeta

“CRL4(CRBN) E3 ubiquitin ligase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109

Studies

The one study Criterium leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01464034Multiple Myeloma · United States2TerminatedJul 2020136

How it is read

Names in the registry

  • “Pomalidomide”, 41 entries
  • “pomalidomide”, 4 entries
  • “Pomalidomide 4 MG Oral Capsule”, 2 entries
  • “Xetrane® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
  • “Imnovid® (Pomalidomide) 4 mg Hard Capsule”, 1 entry

Codes read as this program: CC4047.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.